34 min
The World in a Grain of Sand: Amylyx Pharmaceuticals The World In A Grain Of Sand
-
- Investing
KdT Ventures Partners, Mack Healy & Rima Chakrabarti take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This episode, Amylyx Pharmaceuticals, a neuro biotech founded in a dorm room by two scrappy Brown undergrads. We discuss:
the mechanism of action of Amylyx’s lead disease-modifying asset, and competitive positioning relative to other treatments for neurodegeneration such as aducanumab
Amylyx’s capital efficiency, and reaching PhII trials without a single institutional investor
Amylyx’s unique engagement of ALS patients from the earliest days of the company, helping ensure a strong commercial launch of their ALS therapy
and more
For updates from KdT, please subscribe to our Substack.
KdT Ventures Partners, Mack Healy & Rima Chakrabarti take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This episode, Amylyx Pharmaceuticals, a neuro biotech founded in a dorm room by two scrappy Brown undergrads. We discuss:
the mechanism of action of Amylyx’s lead disease-modifying asset, and competitive positioning relative to other treatments for neurodegeneration such as aducanumab
Amylyx’s capital efficiency, and reaching PhII trials without a single institutional investor
Amylyx’s unique engagement of ALS patients from the earliest days of the company, helping ensure a strong commercial launch of their ALS therapy
and more
For updates from KdT, please subscribe to our Substack.
34 min